INS and COVID-19: Down-regulation of ACE2 is found in patients with COVID-19 that enhances activation of the RAS axis, resulting in decreased insulin and glucose delivery to tissues and impairment of insulin signaling pathways, all of which lead to insulin resistance (54, 55).